High-throughput optofluidic screening for improved microbial cell factories <i>via</i> real-time micron-scale productivity monitoring

Rienzo, Matthew; Lin, Ke-Chih; Mobilia, Kellen C.; Sackmann, Eric K.; Kurz, Volker; Navidi, Adam H.; King, Jarett; Onorato, Robert M.; Chao, Lawrence K.; Wu, Tony; Jiang, Huabei; Valley, Justin K.; Lionberger, Troy A.; Leavell, Michael D.

doi:10.1039/d1lc00389e

Cited by 13 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…76 This California-based company has successfully commercialized fully automated OET instruments to enable the functional screening and selection of individual cells for antibody discovery, 87,88 cell line development, 89,90 cell therapy development 91 and synthetic biology. 92 Microrobots driven by heat-mediated optical manipulation techniques.…”

Section: Recent Advances In Light-driven and Magnetic-driven Microrob...mentioning

confidence: 99%

A review on microrobots driven by optical and magnetic fields

Hou

Wang

et al. 2023

Lab Chip

View full text Add to dashboard Cite

show abstract

Section: Recent Advances In Light-driven and Magnetic-driven Microrob...mentioning

confidence: 99%

A review on microrobots driven by optical and magnetic fields

Hou

Wang

et al. 2023

Lab Chip

View full text Add to dashboard Cite

show abstract

“…Recent advances in single-cell platforms have enabled additional multiplexing capabilities to interrogate neoantigen-specific T cells. The PhenomeX Lightning and Beacon platforms combine optics and fluidics to link phenotypic, functional, and transcriptomic profiles to single neoantigen-reactive T cells ( Figure 2 ) ( 130 ). These technologies can characterize and isolate single cells from a larger population of cells that display desired phenotypes and/or functional characteristics.…”

Section: Single-cell Platformsmentioning

confidence: 99%

Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy

Shah,

Cygan,

Kozlik

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Advancements in sequencing technologies and bioinformatics algorithms have expanded our ability to identify tumor-specific somatic mutation-derived antigens (neoantigens). While recent studies have shown neoantigens to be compelling targets for cancer immunotherapy due to their foreign nature and high immunogenicity, the need for increasingly accurate and cost-effective approaches to rapidly identify neoantigens remains a challenging task, but essential for successful cancer immunotherapy. Currently, gene expression analysis and algorithms for variant calling can be used to generate lists of mutational profiles across patients, but more care is needed to curate these lists and prioritize the candidate neoantigens most capable of inducing an immune response. A growing amount of evidence suggests that only a handful of somatic mutations predicted by mutational profiling approaches act as immunogenic neoantigens. Hence, unbiased screening of all candidate neoantigens predicted by Whole Genome Sequencing/Whole Exome Sequencing may be necessary to more comprehensively access the full spectrum of immunogenic neoepitopes. Once putative cancer neoantigens are identified, one of the largest bottlenecks in translating these neoantigens into actionable targets for cell-based therapies is identifying the cognate T cell receptors (TCRs) capable of recognizing these neoantigens. While many TCR-directed screening and validation assays have utilized bulk samples in the past, there has been a recent surge in the number of single-cell assays that provide a more granular understanding of the factors governing TCR-pMHC interactions. The goal of this review is to provide an overview of existing strategies to identify candidate neoantigens using genomics-based approaches and methods for assessing neoantigen immunogenicity. Additionally, applications, prospects, and limitations of some of the current single-cell technologies will be discussed. Finally, we will briefly summarize some of the recent models that have been used to predict TCR antigen specificity and analyze the TCR receptor repertoire.

show abstract

“…16(a) shows a photograph of the Beacon instrument, developed by Berkeley Lights, and a microfluidic device to work with the Beacon instrument. 258,265 Berkeley Lights' microfluidic devices have up to 14 000 ''NanoPen'' chambers and a microfluidic channel that connects all the ''NanoPen'' chambers for loading/extracting cells, beads, etc. and delivering reagents.…”

Section: Commercializationmentioning

confidence: 99%